Tyra Biosciences
TYRA | NASDAQ
$19.74
-$0.29 (-1.42%)
At close: Nov 16, 2026, 4:00 PM ET
$19.74
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Tyra Biosciences Company Profile
Company profile explainedCompany Profile
Tyra Biosciences, Inc. is a preclinical biopharmaceutical company focused on innovating treatments to tackle tumor resistance and enhance patient outcomes in oncology. Its flagship product candidate, TYRA-300, is a highly selective inhibitor of fibroblast growth factor receptor (FGFR)3, specifically engineered for the treatment of muscle-invasive bladder cancer. Beyond this, the company is advancing a pipeline of programs addressing other critical conditions, including FGFR2-related intrahepatic cholangiocarcinoma, FGFR3-associated achondroplasia, REarranged during transfection (RET) kinase aberrations, and various FGFR4-driven cancers. Tyra also leverages its proprietary SNAP platform, designed to accelerate structural drug design through an iterative molecular 'snapshot' approach. Founded in 2018, Tyra Biosciences maintains its headquarters in Carlsbad, California.
Key Executives
| Name | Position |
|---|---|
| Todd Harris | Co-Founder, CEO, President & Director |
| Alan Fuhrman | Chief Financial Officer |
| Bhavesh Ashar | Chief Operating Officer |
| Robert L. Hudkins | Chief Technology Officer |
| Ali D. Fawaz | General Counsel & Secretary |
| Daniel Bensen | Co-Founder & Chief Discovery Officer |
| Douglas Warner | Chief Medical Officer |
| Julia Rueb | VP of Finance & Principal Accounting Officer |
| Ronald V. Swanson | Chief Scientific Officer |
| Sarah Honig | Senior Vice President of Corporate Development & Strategy |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 27, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Sep 21, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | SC 13D/A | [Amend] Filing |
| Sep 17, 2026 | 4 | Filing |
| Sep 17, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Sep 15, 2026 | 8-K | Current Report |
| Sep 15, 2026 | 424B5 | Filing |
Tyra Biosciences
| Country | United States |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 87 |
| CEO | Todd Harris |
Contact Details
2656 State Street Carlsbad,
California 92008 United States
Stock Details
| Ticker Symbol | TYRA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001863127 |
| CUSIP Number | 90240B106 |
| ISIN Number | US90240B1061 |
| SIC Code | 2834 |
Recent News
- 6 days ago / prnewswire.comTyra Biosciences Reports Third Quarter 2026 Financial Results and Recent Highlights
- 11 days ago / prnewswire.comTyra Biosciences to Participate in Upcoming Investor Conferences
- 1 month ago / zacks.comHere's Why Tyra Biosciences (TYRA) is Poised for a Turnaround After Losing 27% in 4 Weeks
- 2 months ago / prnewswire.comTyra Announces Pricing of $400 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
- 2 months ago / seekingalpha.comTyra Biosciences, Inc. (TYRA) Discusses Initial SURF302 Results on Oral Dabogratinib for Intermediate Risk NMIBC Transcript
- 2 months ago / benzinga.comWhy Is Tyra Biosciences Stock Sinking Wednesday?
- 2 months ago / investors.comTyra Plummets To 10-Month Low On Mixed Bladder Cancer Results
- 2 months ago / barrons.comTyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress
- 3 months ago / prnewswire.comTyra Biosciences Reports Second Quarter 2026 Financial Results and Recent Highlights
- 6 months ago / prnewswire.comTYRA BIOSCIENCES AND BCAN ESTABLISH MAY 21 AS UPPER TRACT UROTHELIAL CANCER (UTUC) AWARENESS DAY
Add to Watchlist
Select watchlists to add or remove TYRA